Assembly Biosciences (NASDAQ: ASMB) is a clinical-stage biotechnology company committed to bringing finite and curative therapies to the 270 million people living with hepatitis B virus (HBV) worldwide. A pioneer in the development of a new class of potent, oral core inhibitor drug candidates, Assembly Bio’s approach aims to break the complex viral replication cycle of HBV to free patients from a lifetime of therapy. Assembly Bio’s strategy toward cure includes a leading portfolio of more potent, next-generation core inhibitors, proof-of-concept combination studies and a research program focused on the discovery of novel HBV targets. 

Biotechnology

Assembly Biosciences

Jason Okazaki

Anuj Gaggar

Zhixin Z.

Suzette DeVito

Qi Huang

John O. Gunderson

Grace Wang

Gayan Bogollaga

Nicole S. White

William Delaney

Jennifer Troia

The executive team at Assembly Biosciences has a history of founding member at Chief, Vice President Human Resources at Sunesis Pharmaceuticals, Inc., Senior Human Resources/Organization Development Consultant at Various Life Sciences organizations, and Vice President, Human Resources at CoMentis, Inc. They all have a degree from University of San Francisco in Human Resources and Organization Development.

CEO and Executive Team

Board of Directors

Leadership Team

CEO and Executive Team

About

Team members

Other teams at Assembly Biosciences

Board of Directors

Leadership Team